Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
S Zhong, … , J D Curb, A R Tall
S Zhong, … , J D Curb, A R Tall
Published June 15, 1996
Citation Information: J Clin Invest. 1996;97(12):2917-2923. https://doi.org/10.1172/JCI118751.
View: Text | PDF
Research Article Article has an altmetric score of 11

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

  • Text
  • PDF
Abstract

Plasma high density lipoprotein (HDL) levels are strongly genetically determined and show a general inverse relationship with coronary heart disease (CHD). The cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to other lipoproteins and is a key participant in the reverse transport of cholesterol from the periphery to the liver. A high prevalence of two different CETP gene mutations (D442G, 5.1%; intron 14G:A, 0.5%), was found in 3,469 men of Japanese ancestry in the Honolulu Heart Program and mutations were associated with decreased CETP (-35%) and increased HDL chol levels (+10% for D442G). However, the overall prevalence of definite CHD was 21% in men with mutations and 16% in men without mutations. The relative risk (RR) of CHD was 1.43 in men with mutations (P < .05); after adjustment for CHD risk factors, the RR was 1.55 (P = .02); after additional adjustment for HDL levels, the RR was 1.68 (P = .008). Similar RR values were obtained for the D442G mutation alone. Increased CHD in men with mutations was primarily observed for HDL chol 41-60 mg/dl; for HDL chol > 60 mg/dl men with and without mutations had low CHD prevalence. Thus, genetic CETP deficiency appears to be an independent risk factor for CHD, primarily due to increased CHD prevalence in men with the D442G mutation and HDL cholesterol between 41 and 60 mg/dl. The findings suggest that both HDL concentration and the dynamics of cholesterol transport through HDL (i.e., reverse cholesterol transport) determine the anti-atherogenicity of the HDL fraction.

Authors

S Zhong, D S Sharp, J S Grove, C Bruce, K Yano, J D Curb, A R Tall

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 Total
Citations: 1 7 3 5 8 11 6 10 6 21 22 33 12 19 12 23 34 25 20 17 12 22 24 21 25 30 17 28 11 1 1 1 488
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2006 (17)

Title and authors Publication Year
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL
VI Zannis, A Chroni, M Krieger
Journal of Molecular Medicine 2006
Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
FC Luft
Journal of Molecular Medicine 2006
The potential for CETP inhibition to reduce cardiovascular disease risk
B Ansell, FD Hobbs
Current Medical Research and Opinion 2006
High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease
M Gomaraschi, L Calabresi, G Franceschini
Expert Opinion on Therapeutic Targets 2006
Plasma lipid transfer proteins
XC Jiang, HW Zhou
Current Opinion in Lipidology 2006
Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease
PJ Barter, JJ Kastelein
Journal of the American College of Cardiology 2006
Aging and high-density lipoprotein metabolism
Y Arai, N Hirose
Aging Health 2006
Cholesteryl ester transfer protein gene mutations in Brazilian hyperalphalipoproteinemia
DB Kaplan, R Schreiber, HC Oliveira, LM Harada, RT Nakamura, HP Pinheiro, J Tentor, ML Cruz, EC Faria
Clinical Genetics 2006
Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol
H Mabuchi, A Inazu
Future Lipidology 2006
Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets
JM Lee, RP Choudhury
Heart (British Cardiac Society) 2006
HDL: The ‘new’ target of cardiovascular medicine
T Sampietro, F Bigazzi, BD Pino, M Puntoni, A Bionda
International Journal of Cardiology 2006
I405V polymorphism of the cholesteryl ester transfer protein (CETP) gene in young and very old people
C Vergani, T Lucchi, M Caloni, I Ceconi, C Calabresi, S Scurati, B Arosio
Archives of Gerontology and Geriatrics 2006
Recent developments in the treatment of atherosclerosis: Review article
PS Brahmkshatriya, MH Jani, MT Chhabria
Journal of Enzyme Inhibition and Medicinal Chemistry 2006
High-density lipoprotein: is it always atheroprotective?
Benjamin J Ansell, Gregg C Fonarow, Alan M Fogelman
Current Atherosclerosis Reports 2006
High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation
PA McPherson, IS Young, B McKibben, J McEneny
Journal of lipid research 2006
Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice
AC Casquero, JA Berti, AG Salerno, EJ Bighetti, PM Cazita, DF Ketelhuth, M Gidlund, HC Oliveira
Journal of lipid research 2006
Familial Dyslipidaemias: An Overview of Genetics, Pathophysiology and Management
SB Hachem, AD Mooradian
Drugs 2006

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 policy sources
Posted by 4 X users
Referenced in 7 Wikipedia pages
Referenced in 1 clinical guideline sources
94 readers on Mendeley
See more details